CAM
COGT icon

ClariVest Asset Management’s Cogent Biosciences COGT Stock Holding History

ClariVest Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-106
Closed -$1K – 696
2022
Q2 		$1K Hold
106
– – ﹤0.01% 595
2022
Q1 		$1K Sell
106
-484
-82% -$3.37K ﹤0.01% 621
2021
Q4 		$5K Buy
590
+484
+457% +$4.21K ﹤0.01% 571
2021
Q3 		$1K Hold
106
– – ﹤0.01% 672
2021
Q2 		$1K Buy
+106
New +$895 ﹤0.01% 665

Other funds holding COGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ClariVest Asset Management's COGT Position: Q3 2022 in Review

ClariVest Asset Management sold out of Cogent Biosciences (COGT) in Q3 2022, closing a stake of 106 shares — an estimated $1K sold.

ClariVest Asset Management first reported a position in COGT in Q2 2021 and held it in 5 quarters. The position peaked at $5K in Q4 2021. 134 funds tracked by Wall St. Rank hold COGT as of Q3 2022.

  • ClariVest Asset Management reported no remaining Cogent Biosciences position as of Q3 2022 after selling out during the quarter.
  • ClariVest Asset Management sold 106 Cogent Biosciences shares in Q3 2022, an estimated $1K.
  • ClariVest Asset Management first reported a position in Cogent Biosciences in Q2 2021 and held it in 5 quarters.
  • ClariVest Asset Management's Cogent Biosciences position peaked at $5K in Q4 2021.
  • 134 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2022.

Based on ClariVest Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.